journal article·2026-06Open access

Liver Kinase B1 in CD11c + Cells Inhibits Fibrosis in Chronic Pancreatitis via the Oncostatin M Signaling

Wenqing Zhang, Shan Guo, Yu Zhang, He Ren, Ke Lei, Chenyang Zhao, Qian Yu, Hongqing Luo, Yujing Xiao, Xiaoming Feng, Xiaoyu Li

Advanced Science· Volume 13· Issue 32

Abstract

ABSTRACT Chronic pancreatitis (CP), characterized by irreversible fibrosis, is a high‐risk factor for pancreatic cancer. Current therapeutic strategies remain inadequate. This study identified a significant increase in CD11c + cells within fibrotic regions of CP patient pancreatic tissues, accompanied by markedly reduced expression of liver kinase B1 (Lkb1) in these cells. Animal experiments confirmed that Lkb1 deletion in CD11c + cells markedly exacerbated pancreatic fibrosis. Further investigation revealed that Lkb1 deletion in CD11c + cells drove the differentiation of monocytes into CD11c + CD206 + mixed‐phenotype macrophages, leading to their accumulation in fibrotic lesions. The CCL2/CCR2 signaling axis was identified as the key pathway mediating the infiltration of these macrophages. Mechanistically, Lkb1 deletion enhanced STAT3 phosphorylation in CD11c + CD206 + macrophages, promoted CCL2 secretion, and thereby promoted more CD11c + CD206 + macrophages to infiltrate. CD11c + CD206 + macrophages activated pancreatic stellate cells (PSCs) via OSM binding to its receptor OSMR, thereby stimulating CCL2 production of PSCs. This recruits additional monocyte‐derived macrophages to sustain PSC activation and exacerbates extracellular matrix (ECM) deposition. Concurrently, neutralization of OSM suppressed CCL2 secretion from PSCs and markedly attenuated pancreatic fibrosis. This study reveals that Lkb1 deletion in CD11c + cells exacerbates CP‐associated fibrosis via the OSM and CCL2/CCR2 axis, thereby presenting a potential therapeutic strategy for CP fibrosis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pancreatitis Pathology and Treatment · Pancreatic and Hepatic Oncology Research · Chemokine receptors and signaling

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Gastroenterology the Affiliated Hospital of Qingdao University Qingdao China

Gastrointestinal Cancer Institute (Pancreatic Disease Institute) the Affiliated Hospital of Qingdao University Qingdao China

Tumor Immunology and Cytotherapy of Medical Research Center Key Laboratory of Pancreatic Disease Clinical Research (Shandong Province) the Affiliated Hospital of Qingdao University Qingdao China

Department of Pathology the Affiliated Hospital of Qingdao University Qingdao China

T‐cell Precision Therapy Lab Department of Pathology and Pathophysiology School of Basic Medical Sciences Hangzhou Normal University Hangzhou China

Funding

National Natural Science Foundation of China · National Science Fund for Distinguished Young Scholars

References (55)

Show source-provided references
1. 10.1016/j.ymthe.2024.06.03010.1016/j.ymthe.2024.06.030 ↗
2. 10.1136/gutjnl‐2023‐33015510.1136/gutjnl‐2023‐330155 ↗
3. 10.1136/gutjnl‐2024‐33222510.1136/gutjnl‐2024‐332225 ↗
4. 10.1056/NEJMcp180939610.1056/NEJMcp1809396 ↗
5. 10.1016/S0140‐6736(24)02187‐110.1016/S0140‐6736(24)02187‐1 ↗
6. 10.1136/bmj‐2023‐07092010.1136/bmj‐2023‐070920 ↗
7. 10.1038/s41422‐019‐0157‐410.1038/s41422‐019‐0157‐4 ↗
8. 10.1016/j.immuni.2024.04.02410.1016/j.immuni.2024.04.024 ↗
9. 10.3389/fphar.2021.81022410.3389/fphar.2021.810224 ↗
10. 10.1038/s41467‐022‐28316‐610.1038/s41467‐022‐28316‐6 ↗
11. 10.1038/s41422‐019‐0161‐810.1038/s41422‐019‐0161‐8 ↗
12. 10.1038/s41423‐024‐01163‐910.1038/s41423‐024‐01163‐9 ↗
13. 10.1038/s41586‐022‐05264‐110.1038/s41586‐022‐05264‐1 ↗
14. 10.1053/j.gastro.2010.04.05510.1053/j.gastro.2010.04.055 ↗
15. Chronic Pancreatitis and Lipomatosis Are Associated With Defective Function of Ciliary Genes in Pancreatic Ductal Cells
16. 10.1038/s41467‐018‐07545‐810.1038/s41467‐018‐07545‐8 ↗
17. 10.1016/j.immuni.2023.07.00110.1016/j.immuni.2023.07.001 ↗
18. 10.1126/sciimmunol.abi976810.1126/sciimmunol.abi9768 ↗
19. 10.1182/bloodadvances.202200771910.1182/bloodadvances.2022007719 ↗
20. 10.1172/jci.insight.16814210.1172/jci.insight.168142 ↗
21. 10.1016/j.immuni.2015.05.01810.1016/j.immuni.2015.05.018 ↗
22. 10.1164/rccm.201303‐0479OC10.1164/rccm.201303‐0479OC ↗
23. 10.1136/gutjnl‐2016‐31365410.1136/gutjnl‐2016‐313654 ↗
24. 10.2337/db20‐063410.2337/db20‐0634 ↗
25. 10.1126/sciimmunol.aax608510.1126/sciimmunol.aax6085 ↗
26. 10.1093/cvr/cvy10910.1093/cvr/cvy109 ↗
27. 10.1038/ncomms815810.1038/ncomms8158 ↗
28. 10.1172/JCI13406610.1172/JCI134066 ↗
29. 10.1016/j.apsb.2023.08.00210.1016/j.apsb.2023.08.002 ↗
30. 10.1186/s12943‐024‐02049‐010.1186/s12943‐024‐02049‐0 ↗
31. 10.1016/j.ccell.2021.05.00210.1016/j.ccell.2021.05.002 ↗
32. 10.1126/sciadv.add263210.1126/sciadv.add2632 ↗
33. 10.1016/j.xcrm.2023.10134810.1016/j.xcrm.2023.101348 ↗
34. 10.1038/s41467‐025‐58753‐y10.1038/s41467‐025‐58753‐y ↗
35. 10.1158/2159‐8290.CD‐18‐126110.1158/2159‐8290.CD‐18‐1261 ↗
36. 10.2337/db09‐028710.2337/db09‐0287 ↗
37. 10.1038/icb.2014.2210.1038/icb.2014.22 ↗
38. 10.1016/j.phrs.2022.10650810.1016/j.phrs.2022.106508 ↗
39. 10.1097/HEP.000000000000118510.1097/HEP.0000000000001185 ↗
40. 10.1016/j.immuni.2023.08.00210.1016/j.immuni.2023.08.002 ↗
41. 10.1097/HEP.000000000000004110.1097/HEP.0000000000000041 ↗
42. 10.1002/advs.20240687610.1002/advs.202406876 ↗
43. 10.1124/pr.119.01844010.1124/pr.119.018440 ↗
44. 10.7150/thno.6541110.7150/thno.65411 ↗
45. 10.1126/science.aan397510.1126/science.aan3975 ↗
46. 10.22203/eCM.v023a0410.22203/eCM.v023a04 ↗
47. 10.1093/ibd/izae09810.1093/ibd/izae098 ↗
48. 10.1038/s41467‐021‐27607‐810.1038/s41467‐021‐27607‐8 ↗
49. 10.1186/s13058‐021‐01430‐x10.1186/s13058‐021‐01430‐x ↗
50. 10.1186/ar431210.1186/ar4312 ↗
51. 10.1093/rheumatology/keac30010.1093/rheumatology/keac300 ↗
52. 10.1097/HC9.000000000000033510.1097/HC9.0000000000000335 ↗
53. 10.1002/hep.3110810.1002/hep.31108 ↗
54. 10.1016/S1470‐2045(16)00078‐410.1016/S1470‐2045(16)00078‐4 ↗
55. 10.7150/thno.7837610.7150/thno.78376 ↗